Muscarinic agonists as enhancers of cognitive flexibility

Patent metadata

Field	Value
Publication number	US-9549928-B2
Application number	US-201214114646-A
Country	US
Kind code	B2
Filing date	Apr 30, 2012
Priority date	Apr 29, 2011
Publication date	Jan 24, 2017
Grant date	Jan 24, 2017

Abstract

Methods and compositions for treating a mental condition in a subject in need thereof, includes administering to a subject in need thereof an effective amount of a CDD-102A compound [5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine], or a pharmaceutically acceptable salt or hydrate thereof pharmaceutically acceptable salt or hydrate thereof.

First claim

What is claimed is:

1. A method of improving a cognitive flexibility function in a human subject having a need thereof, comprising the steps of:
administering to the subject a composition that includes a therapeutically effective amount of at least one M1 agonist compound without substantially producing M2, M3, M4 and/or M5 subtype receptor agonist activity;
wherein the M1 agonist compound is [5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine] (CDD-0102), or a pharmaceutically acceptable salt or hydrate thereof; and
wherein the subject does not have a cholinergic deficit, and does have cognitive deficits not associated with a neurodegenerative disorder; and,
improving the cognitive flexibility function in the subject.

2. The method of claim 1 , wherein the CDD-0102 compound, or a pharmaceutically acceptable salt or hydrate thereof, is administered to the subject in a dose of
about 0.01 mg/kg to about 0.3 mg/kg.

3. The method of claim 2 , wherein the CDD-0102 compound or a pharmaceutically acceptable salt or hydrate thereof, is administered to the subject in a dose between about 0.01 mg/kg and about 0.3 mg/kg, to thereby effect improved behavioral flexibility in the subject.

4. The method of claim 1 , wherein the CDD-0102 compound, or a pharmaceutically acceptable salt or hydrate thereof, is administered to the subject in at least one member selected from the group consisting of a single daily dose, multiple daily doses, two daily doses, three daily doses, four daily doses and five daily doses.

5. The method of claim wherein the CDD-0102 compound, or a pharmaceutically acceptable salt or hydrate thereof, is orally administered to the subject.

6. The method of claim 1 , wherein the subject has one or more neuropsychiatric diseases selected from: dysexecutive syndrome of schizophrenia; Fragile X disease; chronic alcoholism; traumatic brain injury; autism spectrum disorders; attention-deficit hyperactivity disorders; and post-traumatic stress disorder.

7. The method of claim 1 , wherein the subject is a human child.

8. The method of claim 1 , wherein the subject is a human adult.

9. The method of claim 1 , wherein the compound is formulated in a nutraceutical composition and is administered orally.

10. The method of claim 1 , wherein the administration is chronic.

Assignees

• Messer William S
• Ragozzino Michael
• Univ Toledo
• Univ Illinois

Inventors

• Messer William S
• Ragozzino Michael

Classifications

• A61K31/00

  Medicinal preparations containing organic active ingredients · CPC title

• A61K31/506 Primary

  not condensed and containing further heterocyclic rings · CPC title